Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.722 USD | +0.67% | -8.46% | -90.56% |
May. 21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
May. 08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-90.56% | 4.66M | |
+55.94% | 58.06B | |
-5.79% | 40.53B | |
+37.55% | 38.99B | |
+13.21% | 26.7B | |
-12.01% | 26.56B | |
-21.52% | 18.98B | |
+1.28% | 12.17B | |
+23.06% | 12B | |
+26.32% | 11.92B |
- Stock Market
- Equities
- CING Stock
- News Cingulate Inc.
- Maxim Starts Cingulate at Buy With $3 Price Target